ABVC Biopharma Files Amendment to S-1 Registration Statement

TL;DR

<b>ABVC Biopharma is amending its S-1 registration statement, providing updated details for its public offering.</b>

AI Summary

ABVC BIOPHARMA, INC. (ABVC) filed a Amended IPO Registration (S-1/A) with the SEC on March 22, 2024. ABVC Biopharma, Inc. filed an S-1/A amendment on March 22, 2024. The filing is an amendment to a registration statement under the Securities Act of 1933. The company's principal executive offices are located at 44370 Old Warm Springs Blvd., Fremont, CA 94538. The IRS Employer Identification Number is 26-0014658. The company was formerly known as American BriVision (Holding) Corp, METU BRANDS, INC., and ECOLOGY COATINGS, INC.

Why It Matters

For investors and stakeholders tracking ABVC BIOPHARMA, INC., this filing contains several important signals. This amendment updates the company's registration statement, which is a prerequisite for offering securities to the public. The filing provides specific corporate and contact information, essential for investors and regulators to understand the entity.

Risk Assessment

Risk Level: low — ABVC BIOPHARMA, INC. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step and does not inherently indicate new risks or significant changes in the company's risk profile.

Analyst Insight

Monitor future filings for details on the securities offering and the company's progress in its business operations.

Key Numbers

• 2024-03-22 — Filing Date (Date of S-1/A filing)
• 333-276500 — SEC File Number (Registration number for the S-1 filing)
• 26-0014658 — IRS EIN (Employer Identification Number)
• NV — State of Incorporation (State where ABVC Biopharma, Inc. is incorporated)

Key Players & Entities

• ABVC BIOPHARMA, INC. (company) — Filer name
• 2024-03-22 (date) — Filing date
• 44370 Old Warm Springs Blvd., Fremont, CA 94538 (location) — Registrant's principal executive offices
• 26-0014658 (organization_id) — I.R.S. Employer Identification Number
• American BriVision (Holding) Corp (company) — Former company name
• METU BRANDS, INC. (company) — Former company name
• ECOLOGY COATINGS, INC. (company) — Former company name
• Dr. Uttam Patil (person) — Chief Executive Officer

FAQ

Industry Context

ABVC Biopharma operates in the pharmaceutical preparations industry, focusing on the development and commercialization of novel therapies.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public.

What Investors Should Do

1. Review the full S-1/A filing for details on the securities being registered.
2. Track future SEC filings from ABVC Biopharma for updates on their business and financial performance.
3. Research the company's drug pipeline and clinical trial progress.

Key Dates

• 2024-03-22: S-1/A Filing — Amendment to the registration statement filed with the SEC.
• 2016-01-11: Name Change — Date of name change from American BriVision (Holding) Corp.
• 2015-09-08: Name Change — Date of name change from METU BRANDS, INC.
• 2008-08-21: Name Change — Date of name change from ECOLOGY COATINGS, INC.

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previous registration statement, indicating updates or additions to the initial filing.

Key Financial Figures

• $0.001 — , a Nevada corporation (the "Company"), $0.001 par value (the "Common Stock"). These s
• $1.07 — e closing price of our common stock was $1.07 per share. The Selling Stockholders m
• $1,200,000 — LP ("Lind") in the principal amount of $1,200,000 (the "2 nd Lind Note"), at a conversion
• $3.50 — price, which shall be the lesser of (i) $3.50 (the "Fixed Price") and (ii) 90% of the
• $2 — rrant") at an initial exercise price of $2 per share, (c) 30,000 shares of Common
• $0.0001 — 00,000,000 shares authorized, par value $0.0001. Its key Subsidiaries include BioLite B
• $6.30 — mon stock at an exercise price equal to $6.30 per share, exercisable until the fifth
• $10.00 — mon stock at an exercise price equal to $10.00 per share, exercisable until the fifth
• $6.25 — n Statement"). The Units were priced at $6.25 per Unit, before underwriting discounts
• $6,875,000 — xpenses, resulting in gross proceeds of $6,875,000. The Offering was conducted on a firm c
• $1.00 — our common stock was below the minimum $1.00 per share required for continued listin
• $2,500,000 — intain stockholders' equity of at least $2,500,000, and the Company's stockholders' equity
• $1,734,507 — the Company's stockholders' equity was $1,734,507 as of March 31, 2023. In accordance wit

Filing Documents

• ea0202318-s1a3_abvcbio.htm (S-1/A) — 2156KB
• ea020231801ex3-2_abvcbio.htm (EX-3.2) — 142KB
• ea020231801ex23-2_abvcbio.htm (EX-23.2) — 3KB
• image_001.jpg (GRAPHIC) — 22KB
• image_002.jpg (GRAPHIC) — 21KB
• image_003.jpg (GRAPHIC) — 20KB
• image_004.jpg (GRAPHIC) — 5KB
• image_005.jpg (GRAPHIC) — 2KB
• ex23-2_001.jpg (GRAPHIC) — 26KB
• ex23-2_002.jpg (GRAPHIC) — 4KB
• 0001213900-24-025197.txt (&nbsp;) — 9461KB
• abvc-20231231.xsd (EX-101.SCH) — 78KB
• abvc-20231231_cal.xml (EX-101.CAL) — 47KB
• abvc-20231231_def.xml (EX-101.DEF) — 390KB
• abvc-20231231_lab.xml (EX-101.LAB) — 695KB
• abvc-20231231_pre.xml (EX-101.PRE) — 406KB
• ea0202318-s1a3_abvcbio_htm.xml (XML) — 1070KB

RISK FACTORS

RISK FACTORS 8 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 27

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 29

BUSINESS

BUSINESS 54 MANAGEMENT 70

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 75

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 79 RELATED PARTY TRANSACTIONS OF DIRECTORS AND EXECUTIVE OFFICERS OF THE COMBINED COMPANY 80

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 83 SELLING STOCKHOLDERS 85 PLAN OF DISTRIBUTION 86 LEGAL MATTERS 88 EXPERTS 88 WHERE YOU CAN FIND MORE INFORMATION 88 You should rely only on the information contained in this prospectus or in any free writing prospectus that we may specifically authorize to be delivered or made available to you. We and our Underwriter have not authorized anyone to provide you with any information other than that contained in this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus may only be used where it is legal to offer and sell our securities. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We are not making an offer of these securities in any jurisdiction where the offer is not permitted. Unless the context otherwise requires, the terms "ABVC," "we," "us" and "our" in this prospectus refer to ABVC BIOPHARMA, INC., and "this offering" refers to the offering contemplated in this prospectus. i PROSPECTUS CONVENTIONS Except where the context otherwise requires and for purposes of this prospectus only: "American BriVision Corporation" refers to a Delaware corporation and wholly-owned subsidiary of ABVC; "APR" or "annual percentage rate" refers to the annual rate that is charged to borrowers, including a fixed interest rate and a transaction fee rate, expressed as a single percentage number that represents the actual yearly cost of borrowing over the life of a loan; "BioKey" means BioKey, Inc. refers to a California corporation and wholly-owned subsidiary of ABVC; "BioLite" means BioLite Holding, Inc. refer

View Full Filing

View this S-1/A filing on SEC EDGAR